These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 1613879)

  • 1. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy.
    Hug EB; Donnelly SM; Shipley WU; Heney NM; Kaufman DS; Preffer FI; Schwartz SM; Colvin RB; Althausen AF
    J Urol; 1992 Jul; 148(1):47-51. PubMed ID: 1613879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of deoxyribonucleic acid flow cytometry in muscle invasive bladder carcinoma treated with preoperative irradiation and cystectomy.
    Jacobsen AB; Pettersen EO; Amellem O; Berner A; Ous S; Fosså SD
    J Urol; 1992 Jan; 147(1):34-7. PubMed ID: 1729547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder.
    Deliveliotis C; Georgoulakis J; Skolarikos A; Trakas N; Varkarakis J; Albanis S; Protogerou B; Bamias A
    Urol Res; 2005 Feb; 33(1):39-43. PubMed ID: 15258707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Flow cytometric analysis of the DNA content in the urinary bladder cancers treated by radical cystectomy and pre-operative irradiation].
    Toyota K; Nagamori S; Kashiwagi A; Nonomura K; Togashi M; Koyanagi T; Nojima T; Inoue K
    Nihon Hinyokika Gakkai Zasshi; 1992 Dec; 83(12):2050-7. PubMed ID: 1474714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA flow cytometry and neo-adjuvant chemotherapy/radiotherapy in operable muscle-invasive bladder carcinoma. A preliminary report.
    Jacobsen AB; Berner A; Juul M; Ous S; Pettersen EO; Fosså SD
    Eur Urol; 1992; 22(4):316-22. PubMed ID: 1490510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy.
    Fung CY; Shipley WU; Young RH; Griffin PP; Convery KM; Kaufman DS; Althausen AF; Heney NM; Prout GR
    J Clin Oncol; 1991 Sep; 9(9):1533-42. PubMed ID: 1875217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.
    Prout GR; Shipley WU; Kaufman DS; Heney NM; Griffin PP; Althausen AF; Bassil B; Nocks BN; Parkhurst EC; Young HH
    J Urol; 1990 Nov; 144(5):1128-34; discussion 1134-6. PubMed ID: 2122007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of flow cytometric deoxyribonucleic acid measurements of deparaffinized specimens in bladder tumors.
    Miao T; Wang Z; Sang N; Xiong R; Cao S
    Eur Urol; 1992; 21(2):98-102. PubMed ID: 1499623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Chetner MP; Souhami L; Zlotecki RA; Sause WT; True LD
    Oncologist; 2000; 5(6):471-6. PubMed ID: 11110598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder preservation by combined modality therapy for invasive bladder cancer.
    Kachnic LA; Kaufman DS; Heney NM; Althausen AF; Griffin PP; Zietman AL; Shipley WU
    J Clin Oncol; 1997 Mar; 15(3):1022-9. PubMed ID: 9060542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deoxyribonucleic acid flow cytometry in predicting response to radical radiotherapy of bladder cancer.
    Wijkström H; Tribukait B
    J Urol; 1990 Sep; 144(3):646-50; discussion 650-1. PubMed ID: 2117672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deoxyribonucleic acid ploidy and the clinical pattern of grade 2 superficial bladder cancer.
    Neulander E; Kaneti J; Chaimovitz C; Sion-Vardy N; Douvdevani A
    J Urol; 1997 Apr; 157(4):1254-8; discussion 1258-9. PubMed ID: 9120914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective bladder preservation by combination treatment of invasive bladder cancer.
    Kaufman DS; Shipley WU; Griffin PP; Heney NM; Althausen AF; Efird JT
    N Engl J Med; 1993 Nov; 329(19):1377-82. PubMed ID: 8413433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of recurrence and progression in primary superficial bladder cancer with DNA flow cytometry.
    Saracino GA; Ditonno P; Disabato G; Traficante A; Battaglia M; Lucivero G; Selvaggi FP
    Eur Urol; 1992; 21 Suppl 1():26-30. PubMed ID: 1425834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deoxyribonucleic acid content and survival rates of patients with transitional cell carcinoma of the bladder.
    al-Abadi H; Nagel R
    J Urol; 1994 Jan; 151(1):37-42. PubMed ID: 8254829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.